Institute of Molecular Immunology, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
AIDS. 2023 Jan 1;37(1):33-42. doi: 10.1097/QAD.0000000000003408. Epub 2022 Oct 18.
Mycobacterium tuberculosis /human immunodeficiency virus (MTB/HIV) coinfection has become an urgent problem in the field of prevention and control of infectious diseases in recent years. Adoptive cellular immunotherapy using antigen-specific T-cell receptor (TCR) engineered T cells which recognize the specific antigen artificially may have tremendous potential in anti-MTB/HIV coinfection. We have previously successfully identified a MTB Ag85B 199-207 and HIV-1 Env 120-128 peptide-bispecific TCR screened out from peripheral blood mononuclear cells of a HLA-A∗0201 + healthy individual and have further studied that how residues on the predicted complementarity determining region (CDR) 3 of the β chain contribute to the bispecific TCR contact with the peptide-MHC. However, it is not clear which amino acids in the predicted CDR3α of the bispecific TCR play a crucial role in ligand recognition.
The variants in the CDR3α of the bispecific TCR were generated using alanine substitution. We then evaluated the immune effects of the five variants on T-cell recognition upon encounter with the MTB or HIV-1 antigen.
Mutation of two amino acids (E112A, Y115A) in CDR3α of the bispecific TCR caused a markedly diminished T-cell response to antigen, whereas mutation of the other three amino acids (S113A, P114A, S116A) resulted in completely eliminated response.
This study demonstrates that Ser 113 , Pro 114 and Ser 116 in CDR3α of the bispecific TCR are especially important for antigen recognition. These results will pave the way for the future development of an improved high-affinity bispecific TCR for use in adoptive cellular immunotherapy for MTB/HIV coinfected patients.
近年来,结核分枝杆菌/人类免疫缺陷病毒(MTB/HIV)合并感染已成为传染病防控领域的一个紧迫问题。采用抗原特异性 T 细胞受体(TCR)工程化 T 细胞进行过继细胞免疫治疗,人工识别特定抗原,在抗 MTB/HIV 合并感染方面可能具有巨大潜力。我们之前已成功从 HLA-A*0201+健康个体的外周血单个核细胞中筛选出结核分枝杆菌 Ag85B 199-207 和 HIV-1 Env 120-128 肽双特异性 TCR,并进一步研究了β链预测互补决定区(CDR)3 上的残基如何有助于双特异性 TCR 与肽-MHC 的结合。然而,目前尚不清楚双特异性 TCR 预测 CDR3α 中的哪些氨基酸在配体识别中起关键作用。
使用丙氨酸取代生成双特异性 TCR 预测 CDR3α 中的变体。然后,我们评估了这 5 种变体在遇到 MTB 或 HIV-1 抗原时对 T 细胞识别的免疫效应。
双特异性 TCR 预测 CDR3α 中的两个氨基酸(E112A,Y115A)突变导致 T 细胞对抗原的反应明显减弱,而另外三个氨基酸(S113A,P114A,S116A)的突变则导致完全消除反应。
本研究表明,双特异性 TCR 预测 CDR3α 中的丝氨酸 113、脯氨酸 114 和丝氨酸 116 对抗原识别特别重要。这些结果将为未来开发用于 MTB/HIV 合并感染患者过继细胞免疫治疗的改良高亲和力双特异性 TCR 铺平道路。